Skip to main content

Incorporating Novel Therapies in the Management of Psoriasis: The Latest Efficacy, Safety, and Patient Outcomes

In this educational series, participants will learn how allosteric inhibition of TYK2 contributes to both efficacy and safety in psoriasis treatment. Additionally, the series covers safety, efficacy, and the role of TYK2 inhibitors in managing psoriatic disease. Participants will be equipped to devise patient-centric, evidence-based treatment plans for individuals with psoriasis.

This multi-part series is designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis.

This initiative is provided by Paradigm Medical Communications, LLC.

Series Courses